

**Client:** Chi Med  
**Source:** Dow Jones  
**Date:** 10 December 2010

---

## **Hutchison China MediTech Increases Indirect Ownership Of OTC JV**

DJ Hutchison China MediTech Increases Indirect Ownership Of OTC JV

LONDON (Dow Jones)--Hutchison China MediTech Limited (HCM.LN), or Chi-Med, the pharmaceutical and healthcare company based primarily in China, Friday announced the intended indirect increase in its ownership of Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited, or HBYS, one of the companies which comprise Chi-Med's China Healthcare Division.

**MAIN FACTS:**

- HBYS primarily engages in the manufacture and sale of over-the-counter traditional Chinese medicines.
- Chi-Med's wholly-owned subsidiary, Hutchison Chinese Medicine Holding Limited, has entered into agreements with Bestchosen Limited, Dian Son Development Limited and Hutchison BYS Holding Limited, or HGHL, to increase its equity interest in HGHL from 75% to 80%, for a total cash consideration of approximately \$2.7 million.
- HGHL currently indirectly holds 50% interest in HBYS.
- Shares at 0835 GMT unchanged at 500 pence valuing the company at GBP258.67 million.

-By Jana Weigand, Dow Jones Newswires; 44-20-7842-9314; [jana.weigand@dowjones.com](mailto:jana.weigand@dowjones.com)

Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: <http://www.djnewsplus.com/access/al?rnd=20DtM5eic47CpU7V%2Bsgqow%3D%3D>. You can use this link on the day this article is published and the following day.

(END) Dow Jones Newswires  
December 10, 2010 03:36 ET (08:36 GMT)  
Copyright (c) 2010 Dow Jones & Company, Inc.